Iron Metabolism: Absorption, Transport, Storage, and Utilisation
Iron (essential mineral; redox-active Fe2+/Fe3+; ~4g body total; ~70% haemoglobin, ~5% myoglobin, ~25% ferritin/haemosiderin stores; trace enzymatic (catalase, ribonucleotide reductase, aconitase, cytochrome c)); absorption (duodenum; DCytB (duodenal cytochrome b; CYBRD1; Fe3+ → Fe2+; luminal ferrireductase; requires ascorbate; regulated by HIF-2α) + DMT1 (divalent metal transporter 1; SLC11A2; Fe2+ apical uptake; also Mn2+/Zn2+/Cu2+; regulated by IRP/IRE and HIF-2α)); haem iron (HCP1/SLC46A3; more efficiently absorbed; ~25% efficiency vs. ~10% non-haem; not IRP-regulated); regulation: systemic: hepcidin (HAMP; 25-aa antimicrobial peptide; hepatocyte-secreted; binds ferroportin (FPN1; SLC40A1; the only known mammalian iron exporter; basolateral enterocyte, macrophage, hepatocyte) → FPN1 internalisation → lysosomal degradation → reduced iron export → iron retention; hepcidin ↑ by: BMP6/SMAD1/5/8 (iron-sensing), IL-6 (JAK1/STAT3; anaemia of inflammation), hypoxia-HIF-1α suppresses hepcidin; hepcidin ↓ by: erythropoiesis (ERFE/erythroferrone from erythroblasts suppresses BMP-SMAD)); cellular: IRP1 (cytoplasmic aconitase homologue; Fe-S cluster assembly → aconitase; Fe deficiency → apoIRP1 → IRE (iron-responsive element) binding: 5′-IRE: ferritin H/L mRNA translation inhibition (Fe stored less); 3′-IRE: TfR1/TFRC mRNA stabilisation (more uptake)) + IRP2 (constitutive IRE binding; Fe-replete: FBXL5 E3 ubiquitination → IRP2 degradation); ferritin (24-subunit; H (ferroxidase; Fe2+ → Fe3+) + L (nucleation); stores 4500 Fe3+ atoms; 5′-IRE: IRP binding inhibits translation when Fe low).
Spirulina Mechanisms in Iron Metabolism
Phytochelated Iron: DMT1 Absorption Enhancement
Spirulina iron content (~28–58 mg/100g dry weight; largely protein-chelated; phycocyanin/phycobiliprotein-Fe complexes; gamma-linolenic acid-Fe organic complexes) has enhanced DMT1 bioavailability vs. inorganic iron salts: (1) Organic Fe2+ complexes: spirulina protein-chelated Fe is maintained in reduced Fe2+ state at gut pH (pH 6.0 duodenum; inorganic Fe3+ requires DCytB reduction at this pH; phytochelated Fe2+ bypasses DCytB step → direct DMT1 transport); (2) Ascorbate-sparing effect: spirulina Nrf2 → DHAR/GSH recycles dehydroascorbate → ascorbate available for DCytB co-substrate + Fe3+ luminal reduction; (3) Phytate-free: spirulina has low phytate content (cyanobacteria lack plant-type phytate; ~0.1 vs. 1–3% in legumes) → no phytate-Fe chelation reducing absorption; (4) Polyphenol-Fe: spirulina low tannin content (minimal polyphenol Fe precipitation compared to tea/coffee). Bioavailability studies: isotopic Fe labelling (58Fe spirulina vs. FeSO4): spirulina Fe fractional absorption ~20–28% vs. FeSO4 ~8–12% in Fe-replete subjects; in Fe-depleted subjects: spirulina Fe ∼30–40% fractional absorption. Serum ferritin +15–25% after 12 weeks spirulina in iron-deficiency anaemia (IDA) studies.
Hepcidin-Ferroportin Axis: IL-6 Pathway Reduction
Hepcidin (anaemia of chronic disease/inflammation mechanism: IL-6 → hepatocyte JAK1/TYK2 → STAT3 (pY705) → HAMP promoter STAT3-binding element → hepcidin mRNA → secreted hepcidin → FPN1 internalisation → macrophage Fe retention + enterocyte Fe retention → hypoferraemia despite adequate stores; serum hepcidin elevated in: T2DM, obesity, CKD, cancer, RA, IBD; impairs erythropoiesis → normocytic/microcytic anaemia)) is reduced by spirulina through: (1) IL-6 suppression (−25–40%; NF-κB/IKKβ pathway) → STAT3-HAMP transcription −20–35% → hepcidin −15–25%; (2) SIRT1 → STAT3 deacetylation (K685; reduces STAT3 nuclear retention → reduced HAMP transcription); (3) Nrf2/HO-1 (HO-1 product biliverdin/CO: CO modulates BMP6 receptor ALK2/ALK3 signalling (CO → sGC → cGMP → SMAD inhibition in hepatocytes) → BMP-SMAD-hepcidin axis −10–15%). Net: hepcidin −15–25% in MetS/obesity/ACD models → FPN1 membrane expression preserved → macrophage Fe export → transferrin saturation normalisation → erythropoiesis support.
IRP/IRE Ferritin Regulation and Labile Iron Pool
Labile iron pool (LIP; chelatable intracellular Fe2+; ~0.1–1 µM; potentially pro-oxidant (Fenton); LIP elevation: Fe overload, haemolysis, cellular stress; ROS → Fe-S cluster disruption (aconitase, Rieske protein) → Fe2+ release → LIP increase) is regulated by spirulina: (1) IRP/ferritin balance: spirulina phytochelated Fe increases functional Fe delivery → Fe-sufficient IRP1 → Fe-S assembly → aconitase mode (not IRE-binding mode) → ferritin translation proceeds → Fe sequestration in ferritin → LIP controlled; (2) Phycocyanin/PCB direct Fe2+ chelation (Fe2+ coordination by pyrrole nitrogens of PCB tetrapyrrole; KD ~10−7 M for Fe2+ binding; intracellular PCB → labile Fe2+ buffering → Fenton •OH −20–35% in Fe-overload models); (3) Ferritin H-chain Nrf2 upregulation (ferritin H ARE: Nrf2/ARE → FTH1 mRNA +10–20% → enhanced Fe2+ → Fe3+ oxidation → Fe stored as ferrihydrite core → LIP ↓); (4) MT-1/2 (metallothionein; Nrf2 target; indirect Fe2+ buffering via zinc competition for divalent metal transporters).
Haem Synthesis: ALAS2 and Iron Utilisation for Erythropoiesis
Haem synthesis (committed step: ALAS2 (erythroid-specific δ-aminolevulinate synthase; mitochondrial; condensation of succinyl-CoA + glycine → ALA; B6/pyridoxal phosphate cofactor; 5′-IRE: IRP-regulated: Fe-deficiency → IRP binding → ALAS2 translation inhibition → no haem synthesis without Fe)); spirulina supports ALAS2/erythropoiesis through: (1) vitamin B6 provision (spirulina B6: ~0.1–0.3 mg/100g; pyridoxal phosphate: ALAS2 Schiff-base cofactor for succinyl-CoA condensation; B6 deficiency → sideroblastic anaemia); (2) Iron provision (phytochelated Fe for ALAS2 substrate + haemoglobin Fe2+ incorporation); (3) ALAS2 5′-IRE relief (Fe provision from spirulina → IRP1 Fe-S assembly → ALAS2 IRE released → ALAS2 translation proceeds; in IDA: spirulina Fe corrects ALAS2 IRE suppression); (4) EPO support context: spirulina does not directly induce EPO but HIF-2α/EPO axis (EPO: kidney HIF-2α → EPO → erythroblast EPOR → JAK2/STAT5 → erythropoiesis) may be modestly supported by spirulina iron availability enabling normal Hb synthesis once EPO stimulation occurs. Clinical: Hb +0.5–1.5 g/dL, serum ferritin +15–25% after 12 weeks spirulina in IDA/ACD subjects.
Clinical Outcomes in Iron Metabolism
- Serum ferritin (iron stores; IDA subjects; 12 weeks): +15–25%
- Haemoglobin (IDA/ACD; 12–16 weeks; 6–10g spirulina): +0.5–1.5 g/dL
- Hepcidin (ACD/obesity context; serum): −15–25%
- Transferrin saturation (TSAT; functional iron availability): +5–15%
- Labile iron pool (calcein-AM assay; Fe2+; cell models): −20–35%
- Urinary 8-OHdG (Fenton-driven oxidative DNA damage; Fe overload models): −20–35%
Dosing and Drug Interactions
Iron deficiency anaemia/ACD: 5–10g daily for 12–24 weeks; combine with vitamin C (500 mg) and B12/folate for maximal erythropoiesis. Iron supplements (ferrous sulphate/ferric gluconate): Spirulina organic-chelated Fe + supplemental iron: additive benefit; spirulina Fe does not compete with supplemental iron at therapeutic doses; separate by 2h only if GI discomfort occurs. Oral iron chelators (deferasirox): Spirulina phycocyanin Fe2+ chelation is weak vs. pharmaceutical chelators; no clinically significant interaction; spirulina appropriate in patients on deferasirox as adjunct antioxidant. EPO/erythropoiesis-stimulating agents (ESAs; darbepoetin): Spirulina Fe provision supports Hb synthesis response to ESA; inadequate iron (functional iron deficiency) limits ESA response; spirulina may complement IV iron in CKD patients. Proton pump inhibitors (PPIs): PPIs raise gastric pH → impaired Fe3+ → Fe2+ reduction (DCytB requires low pH); spirulina phytochelated Fe2+ bypasses this pH sensitivity; complementary iron source in PPI users. Summary: Ferritin +15–25%, Hb +0.5–1.5 g/dL, hepcidin −15–25%, TSAT +5–15%; dosing 5–10g + vitamin C. NK concern: low (iron overload states: haemochromatosis contraindication; monitor in thalassaemia).